Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)
The rising use of these treatments in patients without diabetes has increased demand and raised questions about access for those with diabetes and obesity
Range of Total Body Weight Loss, Fat Free Mass Loss and Skeletal Muscle Mass Loss by Weight Loss Method
In advanced-stage tumors, cancer cells frequently exhibit numerous genetic alterations and increased oxidative stress [26]
This is slightly higher than tirzepatide (+23 bpm) or semaglutide (+34 bpm), though no increase in serious cardiovascular events was observed in Phase 2
For most people, this feeling was mild to moderate and tended to happen early in the treatment process
